Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis

Lancet

Volumn 349, Issue 9046, 1997, Pages 167-169

  Høiby, Niels ^a   Jarløv, Jens Otto ^b   Kemp, Michael ^b   Tvede, Michael ^b   Bangsborg, Jette Marie ^b   Kjerulf, Anne ^b   Pers, Charlotte ^b   Hansen, Hanne ^b  

^a University of Copenhagen   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; METICILLIN; SULFONAMIDE; TRIMETHOPRIM;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; AXILLA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXCRETION; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; NOSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STAPHYLOCOCCUS EPIDERMIDIS; SWEAT; SWEATING;

EID: 0031016452     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09229-X     Document Type: Note

References (27)

1. Roth RR, James WD. Microbial ecology of the skin. Ann Rev Microbiol 1988; 42: 441-64.
2. Montes LF, Wilborn WH. Anatomical location of normal skin flora. Arch Dermatol 1970; 101: 145-59.
3. Imayama S, Shimozono Y, Hoashi M, et al. Reduced secretion of IgA to skin surface of patients with atopic dermatitis. J Allergy Clin Immunol 1994; 94: 195-200.
4. Jarløv JO, Højbjerg T, Busch-Sørensen, et al. Coagulase-negative staphylococci in Danish blood cultures: species distribution and antibiotic susceptibility. J Hosp Infect 1996; 32: 217-27.
5. Archer GL. Alteration of cutaneous staphylococcal flora as a consequence of antimicrobial prophylaxis. Rev Infect Dis 1991; 13 (suppl 10): 805-09.
6. Hedin G, Hambreus A. Multiply antibiotic-resistant Staphylococcus epidermidis in patients, staff and environment - a one-week survey in a bone marrow transplant unit. J Hosp Infect 1991; 17: 95-106.
7. Dryden MS, Talsania H, McCann M, Cookson BD. The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients. Epidemiol Infect 1992; 109: 97-112.
8. Oppenheim BA, Hartley JW, Lee W, Burnie JP. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. BMJ 1989; 299: 294-97.
9. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019-74.
10. Forstall GJ, Knapp C-C, Washington JA. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob Agents Chemother 1991; 35: 1679-81.
11. Strausbaugh LJ, Bolton WK, Dilworth JA, Guerrant RL, Sande MA. Comparative pharmacology of josamycin and erythromycin stearate. Antimicrob Agents Chemother 1976; 10: 450-56.
12. Sörgel F, Metz R, Naber K, Seelmann R, Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother 1988; 22: 155-67.
13. Jones HE. Problems of resistant dermatophytes. J Am Acad Dermatol 1990; 23: 779-81.
14. Høiby N, Johansen HK, Jarløv JO, et al. Ciprofloxacin in sweat and antibiotic resistance. Lancet 1995; 346: 1235.
15. Jarløv JO, Nissen B, Rosdahl VT, Espersen F. Identification of coagulase-negative staphylococci and typing of Staphylococcus epidermidis by a 4h micromethod. APMIS 1994; 102: 272-78.
16. Ojeniyi B, Hoiby N, Rosdahl VT. Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 1991; 99: 492-98.
17. Tenover FC, Arbeeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-39.
18. Sato K. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in general medicine. New York: McGraw-Hill, 1987: 195-209.
19. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673-78.
20. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 1983; 24: 876-82.
21. Coyle MB, Lipsky BA. Coryneform bacteria in infectious diseases: clinical and laboratory aspects. Clin Microbiol Rev 1990; 3: 227-46.
22. Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994; 22: S111-S121.
23. Sörgel F, Naber KG, Kinzig M, Mahr G, Muth P. Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: A review. Am J Med 1991; 91: 51-66.
24. Takenouchi T, Tabata F, Iwata Y, Manzawa H, Sugawara M, Ohya S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1835-42.
25. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-88.
26. Nikaido H. Prevention of drug access to bacterial targets - permeability barriers and active efflux. Science 1994; 264: 382-88.
27. Sloos JH, Dijkshoorn L, Trienekens TAM, et al. Multitiresistant Staphylococcus epidermidis in a neonatal care unit. Clin Microbiol Infect 1996; 2: 44-49.